The Impact Of SGLT2 Inhibitors On Serum Lipids And Electrolytes In Type 2 Diabetes Mellitus With Chronic Renal Disease: Meta-analysis

Objective:To evaluate the impact of sodium glucose co-transporter 2(SGLT2)inhibitors on serum lipids and electrol ytes in t ype 2 diabetes mellitus(T2DM)with chronic kidney disease(CKD).Methods:Computer retrieval of Web of Science,Pubmed,Cochrane Library,Embase,Wanfang and CNKI literature databases from the establishment of the library to October,2020 about SGLT2 inhibitor on T2 DM combined CKD related literature on the impact of the serum lipid s and electrol ytes,screening literature a ccording to include and exclude standard,extracting data and evaluating the qualit y of the literature,The levels of low densit y lipoprotein cholesterol(LDL-C),high densit y lipoprotein cholesterol(HDL-C),trigl yceride(TG),serum phosphorus,magnesium and calcium were anal yzed using Rev Man5.4 software.Results:A total of 6 randomized controlled studies were included,and a total of 8,129 patients,meta-anal ysis showed that compared with the placebo group,the SGLT2 inhibitor group significantl y increa sed HDL-C levels[OR=1.31,95%C I(1.23,1.38),P<0.00001] and serum magnesium levels[OR=0.70,95%C I(0.50,0.90),P<0.00001],while LDL-C levels [OR=-0.32,95%C I(-4.88,4.2),P=0.89],TG levels [OR=-0.34,95%CI(-14.23,13.55),P=0.96] and serum calcium levels [OR=0.01,95%C I(-0.04,0.06),P=0.66]had no significant effect in T2 DM patients with stage 2CKD and T2 DM patients with stage 3 CKD.In addition,SGLT2 inhibitors increased serum phosphorus levels in T2 DM patients with stage 3 CKD[OR=0.33,95%C I(0.25,0.41),P < 0.00001 ],but had no significant effect on T2 DM patients with stage 2 CKD [OR=0.33,95%CI(-0.16,0.81),P=0.18].Conclusion:1.SGLT2 inhibitors can increase HDL-C levels in T2 DM patients with stage 2 CKD and T2 DM patients with stag e 3 CKD,but have no significant effect on LDL-C and TG levels;2.SGLT2 inhibitors can increase serum magnesium levels in T2DM patients with stage 2 CKD and T2 DM patients with stage 3 CKD,and have no significant effect on serum calcium.SGLT2 inhibitors can increase serum phosphorus levels in T2 DM patients with stage 3 CKD, but have no significant effect in T2 DM patients with stage 2 CKD.